These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 28188806)

  • 1. Role of CCL20 mediated immune cell recruitment in NF-κB mediated TRAIL resistance of pancreatic cancer.
    Geismann C; Grohmann F; Dreher A; Häsler R; Rosenstiel P; Legler K; Hauser C; Egberts JH; Sipos B; Schreiber S; Linkermann A; Hassan Z; Schneider G; Schäfer H; Arlt A
    Biochim Biophys Acta Mol Cell Res; 2017 May; 1864(5):782-796. PubMed ID: 28188806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. c-Rel is a critical mediator of NF-κB-dependent TRAIL resistance of pancreatic cancer cells.
    Geismann C; Grohmann F; Sebens S; Wirths G; Dreher A; Häsler R; Rosenstiel P; Hauser C; Egberts JH; Trauzold A; Schneider G; Sipos B; Zeissig S; Schreiber S; Schäfer H; Arlt A
    Cell Death Dis; 2014 Oct; 5(10):e1455. PubMed ID: 25299780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NF-κB/RelA controlled A20 limits TRAIL-induced apoptosis in pancreatic cancer.
    Geismann C; Hauser C; Grohmann F; Schneeweis C; Bölter N; Gundlach JP; Schneider G; Röcken C; Meinhardt C; Schäfer H; Schreiber S; Arlt A
    Cell Death Dis; 2023 Jan; 14(1):3. PubMed ID: 36596765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRAIL/NF-κB/CX3CL1 Mediated Onco-Immuno Crosstalk Leading to TRAIL Resistance of Pancreatic Cancer Cell Lines.
    Geismann C; Erhart W; Grohmann F; Schreiber S; Schneider G; Schäfer H; Arlt A
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29867042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CCL20 is elevated during obesity and differentially regulated by NF-κB subunits in pancreatic β-cells.
    Burke SJ; Karlstad MD; Regal KM; Sparer TE; Lu D; Elks CM; Grant RW; Stephens JM; Burk DH; Collier JJ
    Biochim Biophys Acta; 2015 Jun; 1849(6):637-52. PubMed ID: 25882704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SKP2 confers resistance of pancreatic cancer cells towards TRAIL-induced apoptosis.
    Schüler S; Diersch S; Hamacher R; Schmid RM; Saur D; Schneider G
    Int J Oncol; 2011 Jan; 38(1):219-25. PubMed ID: 21109943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advancement of NF-κB Signaling Pathway: A Novel Target in Pancreatic Cancer.
    Pramanik KC; Makena MR; Bhowmick K; Pandey MK
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30563089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity.
    Lai SW; Bamodu OA; Tsai WC; Chang YM; Lee WH; Yeh CT; Chao TY
    Clin Exp Metastasis; 2018 Oct; 35(7):663-677. PubMed ID: 29987671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.
    Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Gschwend JE; Simmet T; Debatin KM; Fulda S
    Cancer Res; 2008 Oct; 68(19):7956-65. PubMed ID: 18829553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling.
    Chen X; Kandasamy K; Srivastava RK
    Cancer Res; 2003 Mar; 63(5):1059-66. PubMed ID: 12615723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells.
    Legler K; Hauser C; Egberts JH; Willms A; Heneweer C; Boretius S; Röcken C; Glüer CC; Becker T; Kluge M; Hill O; Gieffers C; Fricke H; Kalthoff H; Lemke J; Trauzold A
    Cell Death Dis; 2018 May; 9(5):445. PubMed ID: 29670075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metallothionein-1G suppresses pancreatic cancer cell stemness by limiting activin A secretion
    Li K; Zhang Z; Mei Y; Yang Q; Qiao S; Ni C; Yao Y; Li X; Li M; Wei D; Fu W; Guo X; Huang X; Yang H
    Theranostics; 2021; 11(7):3196-3212. PubMed ID: 33537082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
    Hari Y; Harashima N; Tajima Y; Harada M
    Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in K-Ras linked to levels of osteoprotegerin and sensitivity to TRAIL-induced cell death in pancreatic ductal adenocarcinoma cells.
    Kanzaki H; Ohtaki A; Merchant FK; Greene MI; Murali R
    Exp Mol Pathol; 2013 Apr; 94(2):372-9. PubMed ID: 23219833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glutamine-mediated epigenetic regulation of cFLIP underlies resistance to TRAIL in pancreatic cancer.
    Kim JH; Lee J; Im SS; Kim B; Kim EY; Min HJ; Heo J; Chang EJ; Choi KC; Shin DM; Son J
    Exp Mol Med; 2024 Apr; 56(4):1013-1026. PubMed ID: 38684915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyper-O-GlcNAcylation is anti-apoptotic and maintains constitutive NF-κB activity in pancreatic cancer cells.
    Ma Z; Vocadlo DJ; Vosseller K
    J Biol Chem; 2013 May; 288(21):15121-30. PubMed ID: 23592772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRAIL Promotes Tumor Growth in a Syngeneic Murine Orthotopic Pancreatic Cancer Model and Affects the Host Immune Response.
    Beyer K; Normann L; Sendler M; Käding A; Heidecke CD; Partecke LI; von Bernstorff W
    Pancreas; 2016 Mar; 45(3):401-8. PubMed ID: 26390425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical link between TRAIL and CCL20 for the activation of TH2 cells and the expression of allergic airway disease.
    Weckmann M; Collison A; Simpson JL; Kopp MV; Wark PA; Smyth MJ; Yagita H; Matthaei KI; Hansbro N; Whitehead B; Gibson PG; Foster PS; Mattes J
    Nat Med; 2007 Nov; 13(11):1308-15. PubMed ID: 17934471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SERP1 is a novel marker of poor prognosis in pancreatic ductal adenocarcinoma patients via anti-apoptosis and regulating SRPRB/NF-κB axis.
    Ma Q; Wu X; Wu J; Liang Z; Liu T
    Int J Oncol; 2017 Oct; 51(4):1104-1114. PubMed ID: 28902358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The anti-CD20 mAb LFB-R603 interrupts the dysregulated NF-κB/Snail/RKIP/PTEN resistance loop in B-NHL cells: role in sensitization to TRAIL apoptosis.
    Baritaki S; Militello L; Malaponte G; Spandidos DA; Salcedo M; Bonavida B
    Int J Oncol; 2011 Jun; 38(6):1683-94. PubMed ID: 21455568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.